HIV Treatment & Management in 2026: Clinical Care, Coding, Reimbursement, and Operational Opportunity

A comprehensive reference guide covering first-line and long-acting HIV regimens, common CPT/HCPCS codes, 2026 Medicare reference payments, ICD-10 codes, and the provider revenue model for HIV care.

By AJ Pakpour — The Business of Modern Medicine™

Educational Summary

HIV care has evolved significantly with the introduction of long-acting injectable regimens and new integrase inhibitor options. This reference guide covers the most commonly used first-line regimens (Biktarvy, Dovato, Triumeq, Symtuza), long-acting and specialty options (Cabenuva, Sunlenca), key ICD-10 codes, common CPT and HCPCS codes for HIV care, and 2026 Medicare reference payment amounts. All reimbursement figures are national averages and must be verified against current CMS data, local MAC policies, and payer contracts. This material is for educational purposes only and does not constitute medical, billing, or coding advice.

Key Takeaways

• ✓First-line HIV regimens include integrase inhibitors (Biktarvy, Dovato, Triumeq) and protease inhibitors (Symtuza)
• ✓Long-acting injectable options (Cabenuva monthly/bimonthly, Sunlenca every 6 months) reduce pill burden for appropriate patients
• ✓Key ICD-10 codes: B20 (HIV disease), Z21 (asymptomatic HIV), Z11.4 (HIV screening), Z20.6 (exposure to HIV)
• ✓Do not interchange B20 and Z21 — code to the patient's documented status
• ✓Drug codes J1961 and J0738 are paid separately using ASP + 6% under Medicare Part B rules
• ✓2026 Medicare reference payments are national averages — actual reimbursement varies by locality, payer, and site of service